NovaBay Pharmaceuticals Announces Partnership With ALPHAEON To Bring Avenova To Ophthalmologists And Their Patients Across the U.S.

By September 24, 2015

IRVINE & EMERYVILLE, Calif. – ALPHAEON Corporation and NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that they have formed a partnership that will add NovaBay’s breakthrough Avenova™ to the products that ALPHAEON makes available to patients and doctors.

Under terms of the agreement, Avenova will now be available for purchase on the ShoutMD® Store, the first social commerce store for lifestyle healthcare products. On ShoutMD, member physicians will now be able to learn about Avenova, rate, review and purchase it for their patients

Avenova product information is now available on the ShoutMD website and will be made available to purchase by their member doctors for online transactions and reward points beginning in early October 2015.

“This partnership will expand our commercial reach, enabling us to offer Avenova to more ophthalmologists throughout the U.S.,” said Ron Najafi, Ph.D., President and CEO of NovaBay. “We believe it will increase revenues for NovaBay, but more importantly, it means that more patients suffering from common, chronic and often-painful eye conditions like blepharitis will finally be able to find relief.”

Avenova is the only lid hygiene product that contains Neutrox, NovaBay’s proprietary pure hypochlorous acid, which mimics a naturally occurring substance produced by white blood cells to fight microbial invaders. Lab tests show that NovaBay’s proprietary formulation of pure hypochlorous acid is effective in solution both at killing microbes and at neutralizing bacterial enzymes and toxins. Those properties enable Avenova to help in managing the symptoms associated with blepharitis and other common eye conditions like meibomian gland dysfunction. Indeed, both patients and doctors report that a regimen of daily lid hygiene using Avenova has been remarkably successful in managing those conditions.

ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare. For more information, please visit

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical eye care market with its two distinct product categories: the NEUTROX™ Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX™ Family of Products includes NEUTROPHASE® for wound care, AVENOVA™ for the eye care market and CELLERX™ for the cosmetic surgery and aesthetic dermatology  market; and its AGANOCIDE® compounds, led by AURICLOSENE™ which is in development as a new drug in urology and dermatology.

NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel), Ophthalmic Instrument Company (New Zealand) and Alpha Pharma LLC (the Ukraine).

In June 2015 NovaBay announced FDA clearance of intelli-Case™, an innovative, easy-to-use device for safely disinfecting soft and rigid gas permeable (RGP) contact lenses with hydrogen peroxide.

Forward-looking Statements:
This press release contains “forward-looking statements.” Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control. Forward-looking statements, such as those regarding potential future product revenue, cannot be accurately predicted or quantified and consequently, actual results may differ materially from those expressed. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

From the Company
Thomas J. Paulson  
Chief Financial Officer
Contact Thomas Paulson

Roy J. Wu
Senior Vice President,
Business Development
Contact Roy Wu

Investor Contact
Jody Cain